Find the right fit for you - faster
Get tailored insights about working at Delfi Diagnostics in one quick step.
Delfi Diagnostics Snapshot
Delfi’s technology was developed to help people live longer, healthier, cancer-free lives by detecting cancer early—when it’s asymptomatic but easier to cure. Millions of high-risk individuals are not getting screened for cancer due to access and cost. A blood-based cancer screening test is easy to incorporate into routine clinical practice, with the potential to impact populations around the world.
Founded in 2019 by Victor Velculescu, a leader in cancer genomics, Delfi Diagnostics is committed to developing high-performing, affordable blood tests for early detection of cancer across multiple tumor types. Leveraging recent advances in cancer biology and machine learning, DELFI's technology can achieve high performance from low-cost, widely available sequencing technology. Delfi Diagnostics has raised over $100 million in seed and series A funding.
